Skinfold thickness gain (mm/week) (high MCT vs low MCT) · promoting short‐term growth of preterm infants
1 finding from 1 review
Weight gain · preterm or low birth weight infants
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
It is very uncertain whether high changes necrotising enterocolitis compared with standard volume of unfortified human milk or term formula (very low certainty).
1 finding from 1 review
Linear growth during hospital stay (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Growth: head circumference (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Extrauterine growth restriction at discharge · preterm or low birth weight infants
High showed no clear difference in extrauterine growth restriction at discharge compared with standard volume of fortified human milk or preterm formula (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
It is very uncertain whether high changes necrotising enterocolitis compared with standard volume of fortified human milk or preterm formula (very low certainty).
1 finding from 1 review
Weight gain · preterm or low birth weight infants
1 finding from 1 review
Linear growth (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Growth: head circumference (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Extrauterine growth restriction at discharge · preterm or low birth weight infants
1 finding from 1 review
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants with or at risk for apnea of prematurity
It is very uncertain whether high‐dose changes side effects (tachycardia, agitation or feed intolerance) leading to… compared with standard‐dose strategies (very low certainty).
3 findings from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
It is very uncertain whether high‐intensity changes usual pain (short‐term) VAS (0 to 10; higher scores mean worse pain) compared with low‐intensity exercise programmes (very low certainty).
2 findings from 1 review
Functional ability · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
It is very uncertain whether high‐intensity changes functional ability (short‐term) FIQ modified (0 to 16; higher scores… compared with low‐intensity exercise programmes (very low certainty).
2 findings from 1 review
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PEG interferon alpha‐2a · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2a compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
4 findings from 1 review
RR 5.66 [0.69, 46.31]
1 study · 81 participants
Low
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.19 [0.79, 1.78]
1 study · 81 participants
Low
Show 1 more finding
PEG interferon (alpha‐2b) · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2b compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
2 findings from 1 review
PEG interferon (combined) · patients on HD with HCV infection
High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).
3 findings from 1 review
RR 4.3 [0.76, 24.33]
2 studies · 97 participants
Moderate
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.05 [0.61, 1.83]
2 studies · 97 participants
Moderate
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found